Abstract
Background: Epithelial ovarian cancer has a poor prognosis, mostly due to its late diagnosis and the development of drug resistance after a first platinum-based regimen. The presence of a specific population of “cancer stem cells” could be responsible of the relapse of the tumor and the development of resistance to therapy. For this reason, it would be important to specifically target this subpopulation of tumor cells in order to increase the response to therapy.
Method: We screened a chemical compound library assembled during the COST CM1106 action to search for compound classes active in targeting ovarian stem cells. We here report the results of the high-throughput screening assay in two ovarian cancer stem cells and the differentiated cells derived from them.
Results and Conclusion: Interestingly, there were compounds active only on stem cells, only on differentiated cells, and compounds active on both cell populations. Even if these data need to be validated in ad hoc dose response cytotoxic experiments, the ongoing analysis of the compound structures will open up to mechanistic drug studies to select compounds able to improve the prognosis of ovarian cancer patients.
Keywords: Cancer stem cell, chemical compounds library, oncology screening, high-throughput screening, ovarian cancer, therapy resistance.
Combinatorial Chemistry & High Throughput Screening
Title:A High-throughput Screening of a Chemical Compound Library in Ovarian Cancer Stem Cells
Volume: 21 Issue: 1
Author(s): F. Ricci*, L. Carrassa, M. S. Christodoulou, D. Passarella, B. Michel, R. Benhida, N. Martinet, A. Hunyadi, E. Ioannou, V. Roussis, L. Musso, S. Dallavalle, R. Silvestri, N. Westwood, M. Mori, C. Ingallina, B. Botta, E. Kavetsou, A. Detsi, Z. Majer, F. Hudecz, S. Bosze, B. Kaminska, T.V. Hansen, P. Bertrand, C. M. Athanassopoulos and G. Damia*
Affiliation:
- IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Via Giuseppe La Masa 19, 20156 Milan,Italy
- IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Via Giuseppe La Masa 19, 20156 Milan,Italy
Keywords: Cancer stem cell, chemical compounds library, oncology screening, high-throughput screening, ovarian cancer, therapy resistance.
Abstract: Background: Epithelial ovarian cancer has a poor prognosis, mostly due to its late diagnosis and the development of drug resistance after a first platinum-based regimen. The presence of a specific population of “cancer stem cells” could be responsible of the relapse of the tumor and the development of resistance to therapy. For this reason, it would be important to specifically target this subpopulation of tumor cells in order to increase the response to therapy.
Method: We screened a chemical compound library assembled during the COST CM1106 action to search for compound classes active in targeting ovarian stem cells. We here report the results of the high-throughput screening assay in two ovarian cancer stem cells and the differentiated cells derived from them.
Results and Conclusion: Interestingly, there were compounds active only on stem cells, only on differentiated cells, and compounds active on both cell populations. Even if these data need to be validated in ad hoc dose response cytotoxic experiments, the ongoing analysis of the compound structures will open up to mechanistic drug studies to select compounds able to improve the prognosis of ovarian cancer patients.
Export Options
About this article
Cite this article as:
Ricci F. *, Carrassa L. , Christodoulou S. M. , Passarella D. , Michel B. , Benhida R. , Martinet N. , Hunyadi A. , Ioannou E. , Roussis V. , Musso L. , Dallavalle S. , Silvestri R. , Westwood N. , Mori M. , Ingallina C., Botta B. , Kavetsou E. , Detsi A. , Majer Z., Hudecz F., Bosze S. , Kaminska B. , Hansen T.V., Bertrand P. , Athanassopoulos M. C. and Damia G. *, A High-throughput Screening of a Chemical Compound Library in Ovarian Cancer Stem Cells, Combinatorial Chemistry & High Throughput Screening 2018; 21 (1) . https://dx.doi.org/10.2174/1386207321666180124093406
DOI https://dx.doi.org/10.2174/1386207321666180124093406 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibitors of Chronically Active Ras: Potential for Treatment of Human Malignancies
Recent Patents on Anti-Cancer Drug Discovery Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions
Current Drug Targets Targeting Hsp90 in Non-Cancerous Maladies
Current Topics in Medicinal Chemistry Differential Gene Expression of BRCA1, ERBB2 and TP53 Biomarkers between Human Breast Tissue and Peripheral Blood Samples of Breast Cancer Patients
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Cdc42-Interacting Protein 4 (CIP4) Impairs Osteosarcoma Tumor Progression
Current Cancer Drug Targets Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design Notch Signalling Pathways and Their Importance in the Treatment of Cancers
Current Drug Targets Determination of the Upper Reference Limit of Human Epididymis Secretory Protein 4 (HE4) in Healthy Male Individuals and Correlation with Renal and Fertility Markers
Endocrine, Metabolic & Immune Disorders - Drug Targets New Derivatives of Bacteriopurpurin with Thiolated Au (I) Complexes: Dual Darkand Light Activated Antitumor Potency
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Anticancer Evaluation of some Newer 2, 5-Disubstituted-1,3, 4-Oxadiazole Analogues
Letters in Drug Design & Discovery Oncotarget Strategies For Herpes Simplex Virus-1
Current Gene Therapy Development of an Efficient Screening System for HDAC Inhibitor Based on TCF Response Element
Anti-Cancer Agents in Medicinal Chemistry Innovations in siRNA Research: A Technology Comes of Age
Recent Patents on Anti-Infective Drug Discovery Anticancer Activity of Lectins from <i>Bauhinia purpurea</i> and <i>Wisteria floribunda</i> on Breast Cancer MCF-7 Cell Lines
Protein & Peptide Letters Implications of Nanotechnology in Healthcare
Nanoscience & Nanotechnology-Asia Advances in Research on Pharmacological Activities and Synthesis of Oleanolic Acid Derivatives at C-3 Position
The Natural Products Journal Data Processing and Analytic Support in the PLCO Cancer Screening Trial
Reviews on Recent Clinical Trials Rationale Design, Synthesis, Cytotoxicity Evaluation, and Molecular Docking Studies of 1,3,4-oxadiazole Analogues
Anti-Cancer Agents in Medicinal Chemistry Targeting the BH3 Domain of Bcl-2 Family Proteins. A Brief History From Natural Products to Foldamers As Promising Cancer Therapeutic Avenues
Current Medicinal Chemistry Development of Novel Therapeutics Targeting the Urokinase Plasminogen Activator Receptor (uPAR) and Their Translation Toward the Clinic
Current Pharmaceutical Design